Samyang Holdings Corporation (Biopharmaceuticals Business) is specialized in the development of small-molecule drugs, new biologic drugs and virus vaccines, and commercialization of DDS-based modified drugs and the first generic for cancer treatment. Samyang is exporting its oncology products and expanding its product portfolio. Samyang’s cytotoxic facility obtained GMP certifications from KR, EU, and JP. The new facility is expected to achieve full cGMP operation. Samyang Biopharm USA Inc. in Cambridge concentrates on global new drug development in immune-oncology and rare diseases. 

● More products on the brochure 

Polymeric Micelle

Genexol®PM (Lyophilized  Injection) - 30mg, 100 mg 
Nanoxel®M  (Lyophilized  Injection) - 20mg, 80 mg 

Generics for Solid Tumors

Paclitaxel (Liquid  Injection) - 30mg, 100mg,  150mg, 300mg/vial
Docetaxel (Liquid  Injection) - 20mg,  80mg, 140mg, 160mg/vial
Oxaliplatin (Liquid  Injection) - 50mg,  100mg, 200mg/vial
Gemcitabine (Liquid  Injection) - 200mg,  1g/vial
Pemetrexed (Liquid  Injection) - 1g/vial, 100mg, 500mg/vial
Pemetrexed (Lyophilized Injection) - 100mg,  500mg/vial
Everolimus (Oral Tablet) - 2.5mg, 5mg,  10mg/tab

Generics for Blood Cancers

Azacitidine (Lyophilized  Injection) - 100mg,  150mg/vial
Decitabine (Liquid  Injection) - 40mg,  50mg/vial
Bortezomib (Lyophilized  Injection) - 2.5mg,  3.5mg/vial
Bendamustine (Liquid  Injection) - 25mg,  100mg/vial
Lenalidomide (Oral  Tablet) - 2.5mg,  5mg, 10mg, 15mg, 20mg, 25 mg/tab

Generics for Supportive Care

Palonosetron (Liquid  Injection) - 0.075mg,  0.25mg, 0.4mg/vial
Zoledronic Acid (Liquid  Injection) - 4mg/vial